Is Salarius Pharmaceuticals Inc (SLRX) overvalued? · $4.9M cap
Salarius Pharmaceuticals Inc (SLRX) is a biotechnology company listed on NASDAQ.
This page asks whether Salarius Pharmaceuticals Inc (SLRX) looks expensive on cached numbers — not a short thesis.
Latest reported SLRX revenue for 2023-03-31 was $0. Net income was -$5.3M. SLRX currently screens at market cap $4.9M.
SLRX currently screens at market cap $4.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SLRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SLRX stock page for the full model, not this heading.
Not investment advice.